<DOC>
	<DOCNO>NCT01053663</DOCNO>
	<brief_summary>This open-label study ass pharmacokinetics safety oseltamivir [ Tamiflu ] 3 cohort infant , age 0-30 day , 31-90 day 91- &lt; 365 day influenza infection . Patients receive 10 dos intravenous oseltamivir [ Tamiflu ] therapy 5 6 day . Optional oral therapy oseltamivir [ Tamiflu ] may consider follow intravenous dose associate pharmacokinetic blood sampling . Evidence continue virus shed day 6 allow 5 additional day ( 10 dos ) oral intravenous administration . Anticipated time study drug 5-11 day . Target sample size &lt; 50 patient .</brief_summary>
	<brief_title>A Study Intravenous Oseltamivir Tamiflu Infants With Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Infant patient Date birth date enrollment &lt; 1 year Diagnosis influenza Duration influenza symptom &lt; /=96 hour prior first dose Parent/guardian willing patient receive intravenous therapy 3 4 day ( 5 6 dos study drug ) Date conception date birth + date birth enrollment &lt; 36 week Creatinine clearance &lt; 30 mL/min/1.73m2 Patients receive form renal replacement therapy baseline Clinical evidence severe hepatic decompensation time enrollment Patients take probenecid medication within 1 week prior study day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>365 Days</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>